HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 04, April 2017 – Diabetes: The Big Picture       » ASEAN+ Rare Disease Network Established       » New Superbug Could Be Epidemic       » China Building World's Largest Multifunctional Nano Research Facility       » NUS Study: Daily Consumption of Tea Protects the Elderly from Cognitive Decline       » Diabetes in Your DNA?       » Wearable Biosensors Can Tell You When to See the Doctor      
BIOBOARD - US
New Data Obtained From Parkinson's Disease Program

Neural stem cell (NSC) potentially provide therapeutic benefit through multiple mechanisms of action including migration to the site of injury, secretion of neurotrophic factors, immunomodulation, cell replacement, and finally recovery of the endogenous neurons. The new data was obtained as part of International Stem Cell Corporation鈥檚 (ISCO) collaboration with the Sanford Burnham Medical Research Institute.

Some results included that NSC migrate a significant distance from the site of implantation in the striatum to the substantia nigra where the loss of dopaminergic (DA) neurons primarily occurs in Parkinson's patients. Additionally no evidence of migration outside the brain was observed.

Another finding was that the stem cell-derived NSC elicited a lower immunogenic response compared with other cell types included in the study, an important safety consideration for allogeneic cell transplantation.

The study conclusively showed that the NSC differentiated post injection in the brain into the specific type of neurons lost in the disease. These new cells replace the neurons destroyed by the disease and produce the neurotransmitter, dopamine, required to alleviate the symptoms.

According to ISCO's, Chief Scientific Officer Dr. R. Semechkin, "These results are important because they establish a solid foundation for the clinical use of neural stem cells for the treatment of Parkinson's diseases. This also potentially opens up a number of other neurological indications, for example Alzheimer's disease, with this cellular product."

Source: International Stem Cell Corporation

Click here for the complete issue.

NEWS CRUNCH  
news Healthcare Sustainability in Asia: Now is the Time to Act — FT Asia Healthcare & Life Sciences Summit 2017
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Rare Diseases
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy